Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Use of Buffered Soluble Alendronate 70 mg (Steovess/Binosto) After Denosumab Discontinuation to Prevent Increase in Bone Turnover

NCT04403698 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT04403698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04403698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Use of Buffered Soluble Alendronate 70 mg (Steovess/Binosto) After Denosumab Discontinuation to Prevent Increase in Bone Turnover
Lead sponsor
University Hospital, Ghent
Phase
Phase 2
Overall status
Completed
Start date
November 13, 2019
Completion date
March 9, 2022
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erosive osteoarthritis